INTRODUCTION
============

Extended-spectrum β-lactamases (ESBLs) produced by Gram-negative bacilli have been a serious problem in hospitalized patients worldwide ([@B1]). These enzymes are most commonly produced by strains of *Klebsiella pneumoniae*, one of the important nosocomial respiratory pathogens. ESBLs have been very prevalent in Korea most being of the types, SHV-12, SHV-2a, and TEM-52, however, CTX-M types have emerged recently as well ([@B2], [@B3]). ESBLs do not hydrolyze cephamycins, however, the cephamycin-hydrolyzing plasmid-mediated AmpC β-lactamase (PABL), CMY-1, emerged in Korea in 1988 ([@B4]). As well, various types of PABLs have been increasingly detected in intrinsically cephamycin-susceptible Gramnegative bacilli in other parts of the world ([@B5], [@B6]). In 2003, 36% and 37% of *K. pneumoniae* isolates at a Korean tertiarycare hospital showed resistance to ceftazidime and cefoxitin, respectively (unpublished data). These results suggest a high prevalence of ESBL and PABL-producing isolates. Recent increases of *K. pneumoniae* isolates concomitantly producing PABL and ESBL pose a serious therapeutic problem as carbapenems remain the only active β-lactams against these organisms ([@B7]).

This study was conducted to determine the prevalence and the types of ESBLs and PABLs among *K. pneumoniae* isolates from respiratory specimens. This information is crucial for controlling of the spread of resistance and for the decision of empirical selection of antimicrobial agents.

MATERIALS AND METHODS
=====================

Clinical isolates and antimicrobial susceptibility testing
----------------------------------------------------------

A total of 373 non-duplicate isolates of *K. pneumoniae*, excluding scant growth, were isolated from the lower respiratory specimens of patients in a Korean tertiary-care hospital in Seoul over a one year period starting in September 2002. The isolates were identified by the conventional methods ([@B8]) or by using the Vitek GNI card (bioMérieux, Marcy I\'Etoile, France).

Antimicrobial susceptibility was tested by the National Committee for Clinical Laboratory Standards (NCCLS) disk diffusion method ([@B9]). ESBL production was detected with the double-disk synergy test with cefotaxime, ceftazidime, aztreonam, cefepime, and amoxicillin/clavulanic acid disks, or phenotypic confirmatory tests as recommended by the NCCLS ([@B9]).

MICs of β-lactams were determined by the NCCLS agar dilution method ([@B9]). Antimicrobial agents used were cephalothin and cefepime (Sigma, St. Louis, MO, U.S.A.), ceftazidime and clavulanic acid (GlaxoSmithKline, Greenford, U.K.), cefotaxime (Aventis, Frankfurt, Germany), cefoxitin and imipenem (Merck/Sharp & Dohme, Rahway, NJ, U.S.A.), and aztreonam (Bristol-Myers Squibb, Princeton, NJ, U.S.A.).

Isoelectric focusing and resistance transfer
--------------------------------------------

Isoelectric focusing was carried out following the manufacturer\'s instructions using pre-cast gels with pH gradient 3-10, and a ThermoFlow Electrophoresis Temperature Control System (Novex Experimental Technologies, San Diego, CA, U.S.A.). Resistance transfer was tested by an agar mating method with nalidixic acid-resistant recipient *E. coli* RG 176, rifampicin-resistant *E. coli* RG 488, or azide-resistant *E. coli* J53. Mueller-Hinton agar containing 100 mg/L of nalidixic acid, rifampicin or azide, and 2 mg/L of ceftriaxone or aztreonam was used to select transconjugants.

Molecular methods
-----------------

PCR for the detection of *bla*~TEM~ and *bla*~SHV~ in the transconjugants was carried out as described previously ([@B10]). PCR for the detection of *bla*~CTX-M~ in ESBL-producing clinical isolates was performed with primers CTXUNI-F (5\'-CVATGTGCA GYACCAGTAA-3\') and CTXUNI-R (5\'-ARGTSACCAG AAYMAGCGG-3\'). A thermocycler (Eppendorf, Hamburg, Germany) was used under the following conditions: 94℃ for 5 min, 35 cycles of 94℃ for 30 sec, 55℃ for 30 sec, and 72℃ for 45 sec, followed by 72℃ for 7 min. PCR for detection of family-specific PABL gene alleles in cefoxitin-intermediate or -resistant isolates was performed by the method of Perez-Perez and Hanson with slight modification ([@B11]). PCR for detection of *bla*~DHA~ in DHA PCR positive isolates was performed using the forward primer DHA1-F (5\'-TCTGCCGCTGAT AATG TCG-3\') for detection of *bla*~DHA-1~ and *bla*~DHA-2~; reverse primers were DHA1-R (5\'-GCCGCCGGATCATTCAGCGC-3\') and DHA2-R (5\'-TCTGCCGGGTCATTCAACAT-3\'), respectively.

Sequencing was performed using the following primers: for *bla*~CTX-M~, CTXM-F (5\'-AAAAATGATTGAAAGGTGGTTGT-3\') and CTXM-R (5\'-TTACAGCCCTTCGGCGATGA-3\'); for *bla*~CMY-1~, CMY1E-F (5\'-TATTAGAGCGGTTTAGGCTG-3\') and CMY1E-R (5\'-AATGTACCGCCCTCTTTC-3\'); for *bla*~CMY-2~, CITS-F (5\'-AACACACTGATTGCGTCTGA-3\') and CITS-R (5\'-TCCTGGGCCTCATCGTCAGTTAT-3\'). Sequencing of *bla*~TEM~, *bla*~SHV~, and *bla*~DHA~ was performed with the primers as described previously ([@B10], [@B11]). DNAs in the PCR products were extracted with a gel extraction kit (Qiagen, Hilden, Germany) and used for direct sequencing of ESBL and PABL genes. Both strands were analyzed by the dideoxy-chain termination method with an ABI 3700 Autosequencer (Perkin-Elmer, Foster City, CA, U.S.A.).

Genomic DNA from *K. pneumoniae* isolates was digested using *Xba*I (Takara, Japan) and separated using a CHEF-DRII system according to the manufacturer\'s instruction (Bio-Rad, Hercules, CA, U.S.A.). The pulsed-field gel electrophoresis (PFGE) band patterns were analyzed with the computer software UVIBand Map V.99 (UVItec Ltd., Cambridge, U.K.) by the un-weighted pair group method using arithmetic averages (UPGMA).

RESULTS
=======

Among the 373 *K. pneumoniae* isolates, 106 (28.4%) tested positive using either the double-disk synergy test or NCCLS confirmatory test, indicating ESBL production. Resistance was transferable in 75 (70.8%) of the isolates. Seventy-six ESBL genes were detected by PCR in 75 transconjugants ([Table 1](#T1){ref-type="table"}).

The most common ESBL type, SHV-12, was identified in 26 of 63 *bla*~SHV~ allele-positive isolates, which showed β-lactamase bands with a pI of 8.2. The second most common type was CTX-M-14, being detected in nine isolates. SHV-2a and TEM-52 were identified in only one and two isolates, respectively.

Forty of 75 (53.3%) clinical isolates with ESBL genes had PABLs. Twenty one contained *bla*~CMY-2~-like, 17 contained *bla*~DHA-1~-like, and two contained *bla*~CMY-1~ ([Table 1](#T1){ref-type="table"}). Antibiotic resistance by disk diffusion method of isolates without ESBL and PABL genes, those with ESBL genes, and those with both ESBL and PABL genes were: to cefoxitin 6%, 3%, and 100%; to aminoglycosides 5-9%, 40-97%, and 90-100%; and to levofloxacin 4%, 60%, and 80%, respectively.

The MIC~90~S of β-lactams to ESBL-producers were: cefotaxime and ceftazidime for both PABL-nonproducer and -producers 64 mg/L and \>128 mg/L, respectively; cefotaxime/clavulanate and ceftazidime/clavulanate for PABL-nonproducer 2 mg/L and 0.25 mg/L, respectively, and PABL-producer 32 mg/L and 128 mg/L, respectively; cefoxitin for PABL-nonproducer and -producer 16 mg/L and \>128 mg/L, respectively ([Table 2](#T2){ref-type="table"}).

PFGE of *Xba*I-digested genomic DNA of 74 ESBL producers showed 19 types including nine subtypes. Twenty-five isolates gave an identical pattern, O1 ([Fig. 1](#F1){ref-type="fig"}), which was mostly isolated from NCU patients. Among these, 18 isolates produced both SHV-12-like and CMY-2-like enzymes.

DISCUSSION
==========

The prevalence of ESBLs among clinical isolates varies depending on countries and institutions. In the United States occurrence of ESBL production in Enterobacteriaceae ranges from 0 to 25%, with the national average being around 3% ([@B1]). ESBL production among *K. pneumoniae* isolates was comparatively higher in Taiwan and Hong Kong, 8.5% and 13%, respectively, but very low in Japan, less than 1% ([@B1]). The prevalence in our study during 2002-2003 was 28.4%, which is significantly higher than the United States, Taiwan, or Hong Kong, but still similar to that of other Korean study ([@B10]).

SHV-12, TEM-52, and SHV-2a were common in the late 1990s in Korea when compared to other countries ([@B2]). In this study, SHV-12-like enzyme remained prevalent (64 of 75), however SHV-2a and TEM-52 were found in only one and two isolates, respectively.

Recently, strains with CTX-M type ESBLs have been increasingly isolated from many parts of the world ([@B1]). In Korea, a few strains harboring CTX-M-14 β-lactamase have been reported since 2000 ([@B3], [@B10]). In this study, nine of 106 isolates harbored CTX-M-14 type ESBLs, indicating a gradual increase of this type.

Since 1989 over 20 types of PABLs have been reported worldwide ([@B6]). In 1995, CMY-1b was reported in Korea with a one amino acid change, Asn346Ile, compared to CMY-1 ([@B5]). It was later renamed CMY-10 ([@B12]). This type was however not detected in this study; neither was CMY-11 which was first identified in *E. coli* in 2002 in Korea ([@B13]).

Korean Antimicrobial Surveillances showed that the cefoxitin-resistance rate of *K. pneumoniae* increased from 14% in 1998 to 20% in 2001 ([@B14]), suggesting dissemination of PABL-producing isolates. In this study, 41 of 75 (54.7%) isolates were cefoxitin resistance, and 40 isolates had PABL genes. Isolates with *bla*~CMY-2-like~ and *bla*~DHA-1-like~ were detected in 21 and 17 isolates respectively, while *bla*~CMY-1~ was found in only two isolates.

CMY-2 (BIL-1, LAT-2) was first identified in *K. pneumoniae* isolates from Greece in 1990 ([@B15]). CMY-2 was the most prevalent and most geographically distributed PABL, with reports from Africa, Europe, India, Taiwan, and the United States ([@B6]). It is a concern that as is ACT-1 enzyme, CMY-2 together with reduced permeability can render the isolate resistant even to imipenem ([@B16], [@B17]).

DHA-1, an inducible PABL, which was first identified in *Salmonella enteritidis* isolated in Saudi Arabia in 1992, has been reported in several other countries including Korea ([@B18], [@B19]). DHA-1-producing *K. pneumoniae* isolates were reported to be especially prevalent in a Korean university hospital ([@B20]).

ESBL or PABL-producing strains were often resistant to aminoglycosides and fluoroquinolones, too. In our study, isolates with both ESBLs and PABLs, were more often resistant to cefoxitin, aminoglycosides, and levofloxacin.

The MIC~90~S of cefotaxime and ceftazidime for ESBL-producing strains were similar to those for strains producing both ESBLs and PABLs. Addition of clavulanic acid cefotaxime and ceftazidime reduced the MIC~90~S for ESBL producers, but not for strains producing both ESBLs and PABLs.

In this study, PFGE of *Xba*I-digested genomic DNA showed that many isolates had the patterns O (29 isolates) and M (13 isolates). Some isolates with different ESBLs, or both ESBLs and PABLs, showed a few identical patterns, implying that both clonal and horizontal spread, and the propensity of *K. pneumoniae* to acquire resistance genes, has a role for their high prevalence in this study.

In conclusion, SHV-12 type ESBL-producing *K. pneumoniae* are increasing among lower respiratory isolates. As well, it seems that CTX-M-14-producing isolates are emerging in Korea. It also seems that the coexistence of PABLs such as CMY-2 and DHA-1 is common. Spreading of ESBL-producing strains with PABL genes is a concern, as it causes limitations in the selection of antimicrobial agents for optimal treatment of patients.
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^\*^The number of isolates with their AmpC genes sequenced is shown in parenthesis.
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